Boston, MA, and San Francisco, CA - The aromatase inhibitors have revolutionized breast-cancer treatment by providing a more effective alternative to tamoxifen. However, Drs David T Felson (Boston ...

Increase in blood pressure in patients with metastatic kidney cancer treated with combination checkpoint inhibitor and vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.

Treatment with an aromatase inhibitor, either alone or in combination with growth hormone (GH), slowed bone advancement and enhanced adult height in mid-pubertal boys with a short predicted adult ...

DEAR DR. ROACH: I am 78 years old. Breast cancer runs in my family, and I am one of the lucky ones who had a lump that was caught early through an annual mammogram. I had a partial mastectomy, which ...

An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine ...

TUESDAY, Sept. 17, 2024 (HealthDay News) -- For postoperative patients with breast cancer, the duration of aromatase inhibitor (AI) treatment is not associated with the risk for coronary artery ...